URO-1

URO-1 is an emerging medical device company developing innovative biopsy instruments to improve prostate cancer diagnosis. Its core technology aims to solve the problem of inadequate tissue sampling by providing longer, less-fragmented cores, which can lead to more accurate pathology and genomic testing. Founded in 2018 and headquartered in Greensboro, NC, the company is privately held and positioned in the diagnostics sector with a clear focus on establishing a new standard of care in soft tissue biopsy.

Medical device platform for soft tissue biopsy, consisting of the SUREcore® needle for obtaining larger, higher-quality tissue cores with minimal artifact and the coreCARE® system for specimen retrieval that preserves tissue integrity and orientation.

URO-1 competes in the crowded biopsy needle market dominated by large players like Boston Scientific, BD, and Medtronic, which offer a wide range of standard core biopsy needles. Its differentiation is a focused engineering effort on core quality and integrity, a niche not heavily emphasized by incumbents. It may also face competition from other specialized startups or from incumbents who could rapidly develop similar technology.